South San Francisco, CA, United States of America

Gyorgy Pal Snell

This inventor holds 11 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignees: Takeda Pharmaceutical Company Limited, Vir Biotechnology, Inc.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gyorgy Pal Snell. Retrieved from https://idiyas.com/inventor/gyorgy-pal-snell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 10)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 17)

Average Co-Inventor Count = 8.0

ph-index = 6

Forward Citations = 77(Granted Patents)

Location History:

San Francisco, CA (US) (2013 - 2022)
South San Francisco, CA (US) (2022)

Company Filing History:

9 out of 1,228

Takeda Pharmaceutical Company Limited

patents

2 out of 8

Vir Biotechnology, Inc.

patents

Years Active: 2013-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12209138 - Anti-CD38 antibodies (2025-01-28),

2. 11479599 - Antibodies against SARS-CoV-2 and methods of using the same (2022-10-25),

3. 11434304 - Anti-CD38 antibodies (2022-09-06),

4. 11168128 - Antibodies against SARS-CoV-2 and methods of using the same (2021-11-09),

5. 10494444 - Anti-CD38 antibodies (2019-12-03),

6. 10336833 - Conjugated anti-CD38 antibodies (2019-07-02),

7. 9790285 - Anti-CD38 antibodies (2017-10-17),

8. 9676869 - Conjugated anti-CD38 antibodies (2017-06-13),

9. 9102744 - Conjugated anti-CD38 antibodies (2015-08-11),

10. 8926969 - Anti-CD38 antibodies (2015-01-06),

11. 8362211 - Anti-CD38 antibodies (2013-01-29),

Title: Gyorgy Pal Snell: Innovator in Antibody Research

Introduction

Gyorgy Pal Snell is a prominent inventor based in South San Francisco, CA (US). He has made significant contributions to the field of antibody research, holding a total of 11 patents. His work focuses on developing innovative therapeutic solutions for various diseases.

Latest Patents

Among his latest patents, Snell has developed anti-CD38 antibodies. These isolated antibodies bind to human CD38 and cynomolgus CD38, and they are accompanied by pharmaceutical compositions that utilize these antibodies for therapeutic and diagnostic methods. Additionally, he has worked on antibodies against SARS-CoV-2, providing solutions that can bind to a SARS-CoV-2 antigen and neutralize infections. This patent also includes polynucleotides that encode the antibodies, vectors, and host cells, along with methods for treating or diagnosing SARS-CoV-2 infections.

Career Highlights

Throughout his career, Snell has been associated with notable companies such as Takeda Pharmaceutical Company Limited and Vir Biotechnology, Inc. His work in these organizations has furthered the development of groundbreaking therapies in the field of immunology.

Collaborations

Some of his notable coworkers include Kathleen Ann Elias and Gregory M Landes. Their collaborative efforts have contributed to the advancement of antibody research and therapeutic applications.

Conclusion

Gyorgy Pal Snell's innovative work in antibody research has led to significant advancements in therapeutic solutions for various diseases. His contributions continue to impact the field positively, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.